Q3-12 Shareholder Letter/MDA...Nothing really new in letter but if Bioniche executes to target dates, and is successful in both launching and acquiring rights to new products for Animal Health division (as discussed in letter, including Sin Susto which we have not heard abourt since initial press release), an interesting summer/ late fall will proceed AGM.
Also, possibly the upcoming May 22nd presentation of Urocidin at AUA might also make things interesting (but, not mentioned in letter). And, of course, VMC and what will be on initial production schedule.
Hopefully link "live" (hit PDF) otherwise can access on ASX BNC site. rg
| 11/05/2012 |
|
Q3 Shareholder Letter, MDA, Financial Stmts, Certificates |
53 |
PDF |